Market Newsdesk

Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key Patent

• Patent protects methods of regulating TNF-α to treat cancers, autoimmune disorders, and other disorders associated with chronic inflammation

BALTIMORE–(BUSINESS WIRE)–
Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”) was issued US Pat. No. 10,835,523 B2, titled “Method of Regulating Tumor Necrosis Factor-Alpha (TNF-α) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation” by the United States Patent & Trademark Office (USPTO). The patent is a continuation of U.S. patent application No. 15/558,094, which was granted as U.S. Patent No. 10,588,899 with claims for treating diabetes.

“We are thrilled to continue building on the foundation that MyMD currently has around regulating TNF-α as a method of treating disorders associated with chronic inflammation,” said Chris Chapman, M.D., Chief Medical Officer of MyMD. “The issuance of this patent supports the continued expansion of indications that our lead compound, MYMD-1, has shown success in treating during preclinical studies.”

MYMD-1 is being developed to treat autoimmune and age-related diseases, including extending the human lifespan. MYMD-1 has been shown to be effective in regulating the immune system from causing age-related diseases in preclinical studies evaluating impact on autoimmune thyroiditis and experimental autoimmune encephalomyelitis. MyMD believes that it is the first oral small molecule selective regulator of TNF-α capable of crossing the blood-brain barrier.

The mechanism of action for MYMD-1 involves regulating the production of TNF-α, offering the potential to reshape clinical guidelines and treatment approaches for a number of autoimmune diseases including diabetes, rheumatoid arthritis and multiple sclerosis, as well as aging, addiction and depression. MyMD has continued to leverage its foundational work in the area of programmed cell death and was previously issued US Pat. No. 10,517,856 B2, titled “Methods of altering programmed cell death and extending cell life,” which showed the method of beneficially altering programmed cell death (or modulating programmed cell life) and how it may postpone the onset of various diseases, extend lifespan, and/or reverse the normal aging process in an individual. These patents, coupled with studies to date have laid the groundwork for the Phase 2 trials for depression in COVID and sarcopenia, expected to be initiated in the first quarter of 2021.

The issuance is the ninth granted patent for MYMD-1, with an additional 20 applications currently pending worldwide.

As previously announced, Akers Biosciences and MyMD Pharmaceuticals announced a definitive merger agreement, whereby the two companies will join as one to focus on developing and commercializing MyMD’s novel immunotherapy pipeline assets. Upon closing the transaction, the combined company is expected to be renamed MyMD Pharmaceuticals Inc and remain listed on the NASDAQ under the new ticker symbol “MYMD.” The closing of merger, however, remains subject to the approval of Akers’ shareholders, as well as other customary closing conditions.

About MyMD Pharmaceuticals, Inc:

MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-α and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-α blocking drugs, and aging and longevity. SUPERA-1R is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. SUPERA-1R is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit www.mymd.com.

About Akers Biosciences Inc.

Akers Biosciences is pursuing rapid development and manufacturing of a COVID-19 vaccine candidate in collaboration with Premas Biotech PVT Ltd.

No Offer or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Important Additional Information Will be Filed with the SEC

In connection with the proposed transaction between Akers and MyMD, Akers intends to file relevant materials with the SEC, including a registration statement that will contain a proxy statement and prospectus. AKERS URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AKERS, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and shareholders will be able to obtain free copies of the proxy statement, prospectus and other documents filed by Akers with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In addition, investors and shareholders will be able to obtain free copies of the proxy statement, prospectus and other documents filed by Akers with the SEC by contacting Investor Relations by mail at Akers Biosciences, Inc., Attn: Investor Relations, 201 Grove Road, West Deptford, NJ 08086. Investors and stockholders are urged to read the proxy statement, prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.

Participants in the Solicitation

Akers and MyMD, and each of their respective directors and executive officers and certain of their other members of management and employees, may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about Akers’ directors and executive officers is included in Akers’ Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 25, 2020, as amended on October 21, 2020, and the proxy statement for Akers’ 2020 annual meeting of stockholders, filed with the SEC on July 29, 2020. Additional information regarding these persons and their interests in the transaction will be included in the proxy statement relating to the transaction when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this communication regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Akers and MyMD undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, risks relating to the completion of the merger, including the need for stockholder approval and the satisfaction of closing conditions; the cash balances of the combined company following the closing of the merger; the ability of Akers to remain listed on the Nasdaq Capital Market in connection with the merger; and expected merger-related cash outlays, including the timing and amount of those outlays. Risks and uncertainties related to MyMD that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates, the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates, the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy.

New factors emerge from time to time and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks, as well as other risks associated with the combination, will be more fully discussed in the proxy statement/prospectus that will be included in the registration statement that will be filed with the SEC in connection with the proposed transaction. Additional risks and uncertainties are identified and discussed in the “Risk Factors” section of Akers’ Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Akers and MyMD as of the date of this release. Neither Akers nor MyMD undertakes any obligation to update such forward- looking statements to reflect events or circumstances after the date of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005600/en/

Investor Contact:

Brett Mass

646-536-7331

[email protected]

www.haydenir.com

Media Contact:

Will Johnson

201-465-8019

[email protected]

www.antennagroup.com

KEYWORDS: New York Maryland United States North America

INDUSTRY KEYWORDS: Biotechnology Other Health Health Pharmaceutical Oncology

MEDIA:

Logo

Logo

ViacomCBS Releases First Environmental, Social and Governance (ESG) Report

NEW YORK–(BUSINESS WIRE)–
ViacomCBS (NASDAQ: VIAC, VIACA) today released its first Environmental, Social and Governance (ESG) Report, Action: ESG at ViacomCBS, highlighting how the company is addressing the ESG impacts that are most important to its business and stakeholders.

The report, released nearly one year after the merger of Viacom and CBS in December 2019, focuses on data through 2019 and the company’s global ESG priorities to date in three core areas: On-screen Content and Social Impact, Workforce and Culture and Sustainable Production and Operations. The report also provides select data and details on ViacomCBS’ efforts thus far in 2020, including the company’s strong response to the ongoing COVID-19 pandemic and events of racial injustice in the United States.

“ViacomCBS is focused on how we use the power of our platforms as content creators to meaningfully impact the issues that matter to our employees, audiences, partners, communities and investors,” said Bob Bakish, President and CEO of ViacomCBS. “As we all continue to cope with the ongoing impact of COVID-19, as well as a racial reckoning in the US, we recognize and embrace our unique role as a global content powerhouse that shapes culture, social attitudes and societal outcomes. We’re committed to the opportunity and responsibility that comes with this reach and are proud to share how our company is taking action in our ESG report.”

The ESG report expands on ViacomCBS’ first materiality assessment, published earlier this year, and is guided by external ESG frameworks, including the Global Reporting Initiative, Sustainability Accounting Standards Board and Task Force on Climate-related Financial Disclosures. It also outlines the company’s alignment with relevant United Nations Sustainable Development Goals, including Gender Equality, Decent Work and Economic Growth and Climate Action.

Among the priority areas addressed in this report, actions by ViacomCBS include:

Responding to COVID-19:

• Committed $100 million to those impacted by the COVID-19 pandemic, including support for non-staff employees on ViacomCBS productions and other entertainment industry workers through third-party organizations and relief funds.
• Worked to keep employees and the public safe and at home during the pandemic by leveraging ViacomCBS brands and on-air talent to amplify official health guidance through the #AloneTogether campaign, which consisted of 174,000 television spots, social media posts and other content across company platforms.

On-screen Content and Social Impact:

• Responded to nationwide protests over victims of racial violence and police killings by donating an additional $5 million to social justice and criminal justice reform organizations, participating in the industry-wide “Blackout Tuesday” day of reflection on June 2 and honoring the death of George Floyd by going dark for eight minutes and 46 seconds on ten networks. The monetary donations build on the company’s standing contributions each year to a range of community organizations.
• Set several new goals to increase diversity behind the camera, including at least 40% representation of Black, Indigenous and People of Color (BIPOC) in the writers’ rooms of CBS and Showtime Network shows during the 2021-22 programming season.

Workforce and Culture:

• Expanded company-wide efforts to strengthen ViacomCBS’ diversity and inclusion, including through its commitment to publicly disclose the diversity data of its workforce.
• Continued to hold its annual Global Inclusion Week, an expansive multi-day experience featuring speakers, immersive sessions and interactive workshops designed to raise awareness and foster conversation about diversity and inclusion, and inspire a sense of engagement and belonging across the company.

Sustainable Production and Operations:

• Committed to reducing its greenhouse gas (GHG) emissions in line with the requirements of the Paris Agreement, continuing a declining trend that saw GHG emissions at legacy Viacom drop by 20% from 2014-2018.
• Increased the number of productions following the Green Production Guide to minimize the environmental impact of filming and derived 10% of the company’s global energy use from renewable sources.

“Whether we’re amplifying diverse voices, championing inclusion and equity in the workplace or crafting a new, more sustainable path for our productions, ViacomCBS is committed to using our reach in the best way possible,” said Crystal Barnes, SVP of Corporate Social Responsibility and ESG. “While we know we have more work to do, this ESG report reflects our dedication to greater transparency and disclosure as we continue to develop our ESG strategy and strengthen our impact in these areas going forward. This is just one of the many steps ahead on our ESG journey.”

To learn more about ViacomCBS’ ESG efforts and to view the full report, please visit https://www.viacomcbs.com/sustainability.

ABOUT VIACOMCBS

ViacomCBS (NASDAQ: VIAC; VIACA) is a leading global media and entertainment company that creates premium content and experiences for audiences worldwide. Driven by iconic consumer brands, its portfolio includes CBS, Showtime Networks, Paramount Pictures, Nickelodeon, MTV, Comedy Central, BET, CBS All Access, Pluto TV and Simon & Schuster, among others. The company delivers the largest share of the US television audience and boasts one of the industry’s most important and extensive libraries of TV and film titles. In addition to offering innovative streaming services and digital video products, ViacomCBS provides powerful capabilities in production, distribution and advertising solutions for partners on five continents.

For more information about ViacomCBS, please visit www.viacomcbs.com and follow @ViacomCBS on social platforms.

VIAC-IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005337/en/

Press:

Pranita Sookai

Director, Corporate Communications

[email protected]

Alexa Cassanos

Vice President, Corporate Communications

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Entertainment Communications Film & Motion Pictures TV and Radio Online Books Other Communications

MEDIA:

Logo

Avolon Announces Early Tender Results of Debt Tender Offers

DUBLIN–(BUSINESS WIRE)–
Avolon Holdings Limited (“Avolon” or the “Company”), the international aircraft leasing company announced today the early results of the previously announced offers to purchase for cash commenced by Avolon Holdings Funding Limited, a Cayman Islands exempted company and a direct wholly-owned subsidiary of Avolon (“Avolon Holdings Funding”) and Park Aerospace Holdings Limited, a Cayman Islands exempted company and a direct wholly-owned subsidiary of Avolon (“Park” and together with Avolon Holdings Funding, the “Offerors,” each an “Offeror” and, together with the Company and its consolidated subsidiaries, “we,” “our” or “us”), for the notes issued by such Offeror, as applicable, listed in the following table (the “Notes”) (i) in accordance with, and in the order of, the corresponding Acceptance Priority Levels and (ii) up to an aggregate purchase price (including principal and premium, but excluding Accrued Interest (as defined below)) of $750,000,000 (the “Maximum Tender Cap”) and subject to possible pro rata allocation, upon the terms and subject to the conditions set forth in the Offer to Purchase (as defined below), and our election, with respect to the Notes validly tendered and not validly withdrawn at or prior to the Early Tender Deadline (as defined below), to make payment for such Notes on December 3, 2020 (the “Early Settlement Date”). The offers to purchase with respect to each series of Notes are being referred to herein as the “Offers” and each, an “Offer.” Each Offer is made upon the terms and subject to the conditions set forth in the offer to purchase, dated November 16, 2020 (as amended or supplemented from time to time, the “Offer to Purchase”). Capitalized terms used but not defined in this press release have the meanings given to them in the Offer to Purchase.

The withdrawal deadline of 5:00 P.M., New York City time, on December 1, 2020 has passed and accordingly, Notes validly tendered pursuant to the Offers may no longer be withdrawn, except in the limited circumstances described in the Offer to Purchase. As of 5:00 P.M., New York City time, on December 1, 2020 (the “Early Tender Deadline”), approximately $849,725,000 aggregate principal amount of the Notes were validly tendered and not validly withdrawn. The table below identifies the principal amount of each Series of Notes validly tendered and not validly withdrawn as of the Early Tender Deadline.

* Admitted to trading on the Irish Stock Exchange plc, trading as Euronext Dublin (“Euronext Dublin”).

All documentation relating to the Offers, including the Offer to Purchase, together with any updates, are available from the Information Agent and the Tender Agent, as set forth below. The Offer to Purchase can also be accessed at the following website: https://www.gbsc-usa.com/avolon/. The Offer to Purchase sets forth a complete description of the terms and conditions of the Offers. Holders of the Notes (“Holders”) are urged to read the Offer to Purchase carefully before making any decision with respect to the Offers.

The Offers will expire at 11:59 P.M., New York City time, on December 15, 2020 (as the same may be extended with respect to any Offer, the “Expiration Date”).

The applicable Total Consideration for each $1,000 in principal amount of the Notes validly tendered and not validly withdrawn before the Early Tender Deadline and accepted for purchase pursuant to the Offers will be determined by reference to a fixed spread specified for each Series of Notes over the yield based on the bid price of the applicable Reference Security, as fully described in the Offer to Purchase. The consideration will be calculated by the Dealer Managers (as defined below) at 10:00 A.M., New York City time, today, December 2, 2020. In addition to the applicable Total Consideration, accrued and unpaid interest from, the last interest payment date up to, but not including, the applicable Settlement Date will be paid in cash on all validly tendered Notes accepted for purchase in the Offers (the “Accrued Interest”). The Total Consideration, plus Accrued Interest, for Notes that are validly tendered and not validly withdrawn at or prior to the Early Tender Deadline and accepted for purchase will be paid by us in same-day funds on the Early Settlement Date.

Our obligation to accept for purchase, and to pay for, Notes that are validly tendered and not validly withdrawn pursuant to each Offer, up to the Maximum Tender Cap and any applicable Series Cap, is conditioned on the satisfaction or waiver by us of a number of conditions set forth in the Offer to Purchase, in each case unless waived by us as provided in the Offer to Purchase.

The amounts of each Series of Notes that are accepted for purchase in the Offer will be determined in accordance with the priorities identified in the column “Acceptance Priority Level” in the table above. Subject to the Maximum Tender Cap and any applicable Series Cap, all Notes validly tendered and not validly withdrawn at or prior to the Early Tender Deadline having a higher Acceptance Priority Level will be accepted for purchase before any validly tendered and not validly withdrawn Notes having a lower Acceptance Priority Level, and all Notes validly tendered after the Early Tender Deadline and at or prior to the Expiration Date having a higher Acceptance Priority Level will be accepted for purchase before any Notes tendered after the Early Tender Deadline and at or prior to the Expiration Date having a lower Acceptance Priority Level. However, any Notes validly tendered and not validly withdrawn at or before the Early Tender Deadline will be accepted for purchase in priority to Notes validly tendered after the Early Tender Deadline and at or prior to the Expiration Date even if the Notes tendered after the Early Tender Deadline and at or prior to the Expiration Date have a higher Acceptance Priority Level than the Notes validly tendered and not validly withdrawn at or before the Early Tender Deadline. Notes of the Series in each Acceptance Priority Level accepted for purchase in accordance with the terms and conditions of the Offers may be subject to proration such that we will only accept for purchase Notes with an aggregate purchase price up to the Maximum Tender Cap or any applicable Series Cap.

We expressly continue to reserve the right, in our sole discretion, to further amend, extend or, upon failure of any condition described in the Offer to Purchase to be satisfied or waived, to terminate any of the Offers, including the right to further amend or eliminate the Maximum Tender Cap or any applicable Series Cap, at any time at or prior to the Expiration Date.

Deutsche Bank Securities Inc., Mizuho Securities USA LLC and Wells Fargo Securities, LLC are serving as the Lead Dealer Managers, and Barclays Capital Inc., BNP Paribas Securities Corp. and MUFG Securities Americas Inc. are serving as Co-Dealer Managers, in connection with the Offers (collectively, the “Dealer Managers”). Questions regarding terms and conditions of the Offers should be directed to Deutsche Bank Securities, Inc. by calling toll free at 866-627-0391, Mizuho Securities USA LLC by calling toll free at 866-271-7403 or to Wells Fargo Securities, LLC by calling toll free at 800-645-3751

Global Bondholder Services Corporation has been appointed as information agent (the “Information Agent”) and tender agent (the “Tender Agent”) in connection with the Offers. Questions or requests for assistance in connection with the Offers or the delivery of tender instructions, or for additional copies of the Offer to Purchase may be directed to Global Bondholder Services Corporation by calling toll free at 866-807-2200 or collect at 212-430-3774 or via e-mail at [email protected] You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Offers.

None of Avolon Holdings Funding, Park, the Company, the Dealer Managers, Global Bondholder Services Corporation, the trustee under the indenture governing the Notes or any of their respective affiliates is making any recommendation as to whether Holders should tender any Notes in response to the Offers. Holders must make their own decision as to whether to tender any of their Notes and, if so, the principal amounts of Notes to tender.

This press release is for informational purposes only and is not an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities. Neither this press release nor the Offer to Purchase, or the electronic transmission thereof, constitutes an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities, as applicable, in any jurisdiction in which, or to or from any person to or from whom, it is unlawful to make such offer or solicitation under applicable securities laws or otherwise. The distribution of this press release in certain jurisdictions may be restricted by law. In those jurisdictions where the securities, blue sky or other laws require the Offers to be made by a licensed broker or dealer and the Dealer Managers or any of their respective affiliates is such a licensed broker or dealer in any such jurisdiction, the Offers shall be deemed to be made by the Dealer Managers or such affiliate, as the case may be on behalf of the Company in such jurisdiction.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSE OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014.

This announcement is released by the Offerors (as defined below) and may contain inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (“MAR”), encompassing information relating to the Notes (as defined below). For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/155, this announcement is made by the directors of each Offeror.

About Avolon

Headquartered in Ireland, with offices in the United States, Dubai, Singapore, Hong Kong and Shanghai, Avolon provides aircraft leasing and lease management services. Avolon is 70% owned by an indirect subsidiary of Bohai Leasing Co., Ltd., a public company listed on the Shenzhen Stock Exchange (SLE: 000415) and 30% owned by ORIX Aviation Systems, a subsidiary of ORIX Corporation which is listed on the Tokyo and New York Stock Exchanges (TSE: 8591; NYSE: IX). Avolon is the world’s third largest aircraft leasing business with an owned, managed and committed fleet, as of 30 September 2020 of 837 aircraft.

Website: www.avolon.aero

Twitter: @avolon_aero

Note Regarding Forward-Looking Statements

This document includes forward-looking statements, beliefs or opinions, including statements with respect to Avolon’s business, financial condition, results of operations and plans. These forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond our control and all of which are based on our management’s current beliefs and expectations about future events. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as “believe,” “expects,” “may,” “will,” “could,” “should,” “shall,” “risk,” “intends,” “estimates,” “aims,” “plans,” “predicts,” “continues,” “assumes,” “positioned” or “anticipates” or the negative thereof, other variations thereon or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. Forward-looking statements may and often do differ materially from actual results. No assurance can be given that such future results will be achieved, that any private placement of senior unsecured notes will occur following the investor calls or, regardless of whether a private placement of senior unsecured notes is consummated, that any ratings agencies will upgrade Avolon to investment grade. Avolon does not intend, and undertakes no duty, to update any information contained herein to reflect future events or circumstances, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005553/en/

Ross O’Connor

Head of Investor Relations

[email protected]

T: | +353 1 231 5818

Emmet Moloney

Head of Communications

[email protected]

T: | +353 1 556 4429

Jonathan Neilan

FTI Consulting

[email protected]

M: | +353 86 231 4135

KEYWORDS: Ireland Europe

INDUSTRY KEYWORDS: Transportation Finance Travel Professional Services Air Aerospace Transport Manufacturing

MEDIA:

Logo

Darkness Rises and For Honor Team Up in Global Collaboration

Players Can Soon Experience For Honor Character Designs, Pets and Special Events

LOS ANGELES–(BUSINESS WIRE)–Darkness Rises, Nexon’s third-person action mobile role-playing game (RPG), will soon be joining forces with Ubisoft’s highly-acclaimed action game, For Honor, in a brand new global collaboration coming to players on December 15.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201202005201/en/

Darkness Rises (Graphic: Business Wire)

The Darkness Rises X For Honor collaboration will allow players to experience battles donning Darkness Rises character costumes modeled after fan-favorite For Honor classes, including Kensei, Peacekeeper, Nobushi, Hulda, Warden, Raider, and Black Prior. For Honor factions, Knights, Vikings and Samurai will also be the basis for three new Darkness Rises collaboration pets.

Additionally, there will be various in-game packages for players that can enhance the gameplay experience, including collaboration costumes and For Honor Pet Eggs.

From December 15 through March 16, 2021, live event rewards within the update will include:

• Clear Mission Rewards – Players can receive Rank A++ Armor Chests, Rank S Polish Chests, and Rank S For Honor Pet Eggs for completing missions and participating in the events.

• Ranking Achievement Reward – As players move up in the ranks in the special collaboration Event PvP Brawl, they can be rewarded with Rank S++ For Honor Costume chests, and can even win full For Honor outfits if they reach the top rank.

To join in on the Darkness Rises X For Honor collaboration, players can download the game for iOS or Android.

Assets:

• Darkness Rises X For Honor Collaboration Assets

Social Media: Twitch / Facebook / Instagram / Twitter / Discord

About Darkness Riseshttps://dr.nexon.com/

Launched in 2018, Darkness Rises is a revolutionary, next-gen action RPG from Nexon that combines breathtaking graphics, state-of-the-art immersive gameplay and harrowing boss battles right in the palm of your hands. Featuring unique classes and beautifully rendered battles on iOS and Android, Darkness Rises has amassed over 23 million players, 35 million curated characters and 2.4 million completed quests since launch.

About Nexon America Inc. https://www.nexon.com

Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO) with more than 80 live games operated across more than 190 countries, is a global leader in online games. Nexon America introduced micro-transactions and the free-to-play business model in the Western market and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Nexon is listed on the Tokyo Stock Exchange, and the company was placed on the Nikkei Stock Index 300 in 2017.

About For Honor https://forhonor.ubisoft.com

Developed by Ubisoft Montreal in collaboration with other Ubisoft studios,** For Honor offers an engaging campaign and thrilling multiplayer modes. Players embody warriors of the four great factions – the bold Knights, the brutal Vikings, the deadly Samurai and the fearsome Wu Lin – fighting to the death on intense and believable melee battlefields. The Art of Battle, the game’s innovative combat system that puts players in total control of their warriors, allows them to utilize the unique skills and combat style of each hero to vanquish all enemies who stand in their way. *Associate Ubisoft studios include Quebec, Toronto and Blue Byte. Additional development from Studio Gobo.

© 2020 Ubisoft Entertainment. All Rights Reserved. Ubisoft and the Ubisoft logo are registered or unregistered trademarks of Ubisoft Entertainment in the US and/or other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005201/en/

Media Contact Information

Nexon America

Cynthia Lezama

[email protected]

KEYWORDS: Australia/Oceania United States United Kingdom Canada North America Australia Europe California

INDUSTRY KEYWORDS: Entertainment Other Consumer Consumer Online Mobile Entertainment Electronic Games

MEDIA:

Photo

Darkness Rises (Graphic: Business Wire)

Logo

Quick Service, Fast Casual Restaurants Fare Best During Non-Traditional Year

Media Contact:
Chuck Tanowitz
Paytronix Systems, Inc.
[email protected]
617-871-2319

Respondents’ Goals for 2021 Include Paying Off Debt and Increasing Savings

Gabrielle Costello
Provident Bank
215-825-9658
[email protected]